Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome

NCT04400032 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Acute Respiratory Distress Syndrome
Covid19

Interventions

BIOLOGICAL: Mesenchymal Stromal Cells

Sponsor

Ottawa Hospital Research Institute

Collaborators

[object Object]
[object Object]